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Abstract: Immune checkpoint blockade targeting PD-1 (PDCD1)/PD-L1 (CD274) is increasingly
used for multiple cancers. However, efficacy and adverse-related events vary significantly. This
bioinformatic study interrogated molecular differences pertaining to PDCD1/CD274 and their
correlated genes on a pan-cancer basis to identify differences between cancer types. Patient RNA-seq
data from fifteen cancer types were accessed on cBioPortal to determine the role of PDCD1/CD274 in
patient survival and to identify positively and negatively correlated genes, which were also assessed
for clinical relevance. Genes correlating with PDCD1/CD274 across multiple cancers were taken
forward for drug repurposing via DRUGSURV and microRNA analysis using miRDB and miRabel.
MicroRNAs were also screened for clinical relevance using OncomiR. Forty genes were consistently
correlated with PDCD1/CD274 across multiple cancers, with the cancers themselves exhibiting a
differential role for the correlated genes in terms of patient survival. Esophageal and renal cancers in
particular stood out in this regard as having a unique survival profile. Forty-nine putative microRNAs
were identified as being linked to the PDCD1/CD274 network, which were taken forward and further
assessed for clinical relevance using OncomiR and previously published literature. One hundred
and thirty significant survival associations for 46 microRNAs across fourteen groups of cancers were
identified. Finally, a total of 23 putative repurposed drugs targeting multiple components of the
PDCD1/CD274 network were identified, which may represent immunotherapeutic adjuvants. Taken
together, these results shed light on the varying PDCD1/CD274 networks between individual cancers
and signpost a need for more cancer-specific investigations and treatments.
Keywords: immunotherapy; immune checkpoint blockade; cBioPortal; bioinformatics; computa-
tional biology; survival analysis; OncomiR; microRNAs
1. Introduction
While cancer immunotherapy has a rich and interesting history [1], recent advances
in our understanding of the complex interactions between the tumor and immune cells
have provided the opportunity to exploit the power of the immune system for the benefit
of patients. A range of different approaches have been explored in the past including the
use of cytokines, anti-tumor antibodies, adoptive cell transfer, and cancer vaccines, with
the use immune checkpoint blockade agents coming to prominence over the last decade.
Immune checkpoint molecules include cytotoxic T lymphocyte-associated protein 4
(CTLA-4) and programmed cell death protein 1 (PDCD1, PD-1). Both molecules act to
inhibit T lymphocytes—CTLA-4 acts to block T cell co-stimulatory signaling via preventing
the interactions between CD28 and CD80/86, and PD-1 via T cell inhibitory signaling upon
engagement with its ligands PD-L1 (CD274) and PD-L2 (PDCD1LG2). Strategies that block
these T cell-inhibitory molecules have proved successful in unleashing the patient’s own T
cell immunity against tumor antigens in cancer.
PDCD1 was first described in 1992 [2] and analysis of knockout mouse models re-
vealed the role it plays in suppressing T cell responses with the development of autoim-
munity in its absence [3,4]. Expression of CD274 ligands on tumor cells was found to
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contribute to tumor immune evasion and, in mouse models, antibody-mediated blockade
of CD274 caused suppression of transplanted melanoma tumor growth [5]. Based on these
observations nivolumab, a fully humanized anti-PDCD1 antibody, was developed and
approved for treatment, initially for malignant melanoma. Since then, a variety of other
agents have been developed including those targeting CD274 (atezolizumab, avelumab,
and durvalumab) as well as PDCD1 (pembrolizumab and cemiplimab). The range of
approved cancers has also grown to include small and non-small cell lung cancer, renal
cell carcinoma, squamous cell head and neck carcinoma, non-Hodgkin lymphoma, gastric
cancer, triple negative breast cancer, and cervical cancer, among others (reviewed in [6]).
Recent meta-analyses of the efficacy of antibodies targeting PDCD1/CD274 as
monotherapy [7,8] found that this treatment is associated with more tumor responses
and increased overall survival (OS) compared to conventional therapy. Although there
are some patients who show long-term complete responses [9,10], the average response
rate is 20% with significant differences across different tumor types [8]. It is of significant
interest to identify the minority of patients who will benefit from immune checkpoint
blockade to better direct this therapy and avoid the (often immune-mediated) adverse
events [11]. Higher objective response rates to PDCD1/CD274 monotherapy have been
associated with a number of factors, including immunogenicity of the tumor [8], male
sex, age < 65 years, current and former smokers, a lack of central nervous system or liver
metastasis, and a lack of EGFR mutations [7]. Therapy responses are not limited to those
cancers in which CD274 expression is detected but high CD274 is associated with a greater
response [8,12,13]. In contrast, high levels of serum [14] or exosomal [15] CD274 have been
associated with non-responders.
One approach to increase the pool of patients who benefit from checkpoint blockade
therapy is to explore combination therapy. A recent analysis of clinical trials found that
PDCD1/CD274 monotherapy studies are declining from a peak in 2017, while combi-
nation therapies show consistent increases over time and represent a large majority of
recent trials [16]. A range of different agents have been explored in combination, includ-
ing chemotherapy and interventions targeting CTLA-4 and VEGF [16]. An early study
in melanoma found that the combination of the anti-CTLA-4 antibody ipilimumab plus
nivolumab (anti-PD-1) resulted in responses greater than those seen in monotherapy tri-
als [17]. At maximum acceptable doses, objective responses were observed in 53% of
patients, with responding patients showing tumor reduction of at least 80% [17]. Identifica-
tion of appropriate adjuvant therapies is of considerable interest, with the repositioning of
previously approved drugs potentially minimizing the cost and time needed for clinical
use approval [18].
This exploratory study uses a bioinformatic approach to examine the impact of mRNA
levels of PDCD1, CD274, and genes showing correlated expression levels on the survival
outcome of a range of cancers. Based on a panel of genes predicted to impact patient
outcomes, potential therapeutic strategies were explored including the prediction of mi-
croRNAs and identification of approved drugs capable of targeting the relevant proteins.
In this way, additional therapeutic targets, likely to complement direct PDCD1/CD274
antibody targeting, are identified.
2. Results
2.1. Impact of CD274 and PDCD1 Expression on Cancer Patient Survival
To assess the importance of CD274 expression on patient survival, the cBioPortal
database was accessed due to its wealth of patient-level omics data [19,20]. Data selection
was performed on studies containing “mRNA expression z-scores relative to diploid sam-
ples (RNA Seq V2 RSEM)” analysis, as described in the Materials and Methods. Individual
studies were collated on a per-cancer type basis and patients were split by the median
CD274 expression into high (red) and low (blue) groups on the Kaplan–Meier curves below
in Figure 1:






Figure 1. Statistically significant Kaplan–Meier plots for pan-cancer CD274 expression. In all cases, overall survival in
months can be seen on the x-axis whilst percentage survived is shown on the y-axis. In all cases, high CD274 expression
is shown in red whilst low CD274 expression is shown in blue. Data were generated using the mRNA expression z-
scores relative to diploid samples (RNA Seq V2 RSEM) for the studies described in the Materials and Methods. CD274
expression was a significant factor for patient survival only in breast cancer (A), melanoma (B), and renal cancer (C). As
such, bladder, cervical, colorectal, esophageal, gastric, head and neck, liver, lung, lymphoma, mesothelioma, ovarian, and
pancreatic cancers have not been shown here but are available in Figure S1. Additionally, the mesothelioma study included
(Mesothelioma (TCGA, Firehose Legacy)) lacked usable Kaplan–Meier survival data.
Only melanoma, breast, and renal cancers demonstrated a statistically significant
difference in patient survival between the low and high expression groups. Other cancers,
detailed in the legend of Figure 1, have thus been excluded from the graph but can be
seen in Figure S1. Strikingly, for the patient cohorts and cancer types selected, high CD274
expression appeared to be beneficial for breast cancer (Figure 1A), melanoma (Figure 1B),
and renal cancer (Figure 1C) patients.
In addition to CD274, analysis of PDCD1 expression was also performed. Although
PDCD1 most typically relates to its expression on tumor-infiltrating lymphocytes (TILs),
there is increasing evidence of tumor-intrinsic PDCD1 expression. In the case of melanoma,
for example, tumor-intrinsic PDCD1 expression exhibits an oncogenic effect, whereas in
lung cancer the blockade of tumor-intrinsic PDCD1 expression promoted proliferation [21].
As such, to further understand the impact of PDCD1 between different cancer types, it is
essential to also consider PDCD1 expression, as shown below in Figure 2:




Figure 2. Statistically significant Kaplan–Meier plots for pan-cancer PDCD1 expression. In all cases, overall survival in
months can be seen on the x-axis whilst percentage survived is shown on the y-axis. In all cases, high PDCD1 expression is
shown in red whilst low PDCD1 expression is shown in blue. Data were generated using the mRNA expression z-scores
relative to diploid samples (RNA Seq V2 RSEM) for the studies described in the Materials and Methods. PDCD1 expression
was a significant factor for patient survival only in bladder cancer (A), breast cancer (B), esophageal cancer (C), head and
neck cancer (D), and melanoma (E). As such, cervical, colorectal, gastric, liver, lung, lymphoma, mesothelioma, ovarian,
renal, and pancreatic cancers have not been shown here but are available in Figure S2. Additionally, the mesothelioma study
included (Mesothelioma (TCGA, Firehose Legacy)) lacked usable Kaplan–Meier survival data.
Interestingly, several cancers which did not show significant effects for CD274 for
the patient cohorts selected demonstrated significant impact of PDCD1 expression on
Int. J. Mol. Sci. 2021, 22, 5478 5 of 20
patient survival, including bladder cancer, esophageal cancer, and head and neck cancer.
Conversely, renal cancer demonstrated a significant effect of CD274 expression on patient
survival (Figure 1C) but did not show an effect of PDCD1. Melanoma and breast cancer
both demonstrated that high expression of CD274 was significantly associated with patient
survival (Figure 1A,B) and showed largely the same pattern for PDCD1 (Figure 2B,E).
Of the five cancers that demonstrated a significant role for PDCD1 in patient survival,
esophageal cancer stood out with low PDCD1 expression being beneficial for the patient
cohort (Figure 2C), whereas the other four cancers all showed high PDCD1 expression to
be beneficial (Figure 2A,B,D,E). The difference in clinical relevance of CD274 and PDCD1
points to the unique molecular biology of each individual cancer type and highlights a need
to identify where the differences lie. This indicates the individuality of tumor immunogenic
responses and prompts a need for further molecular insight.
2.2. Identification of Genes That Correlate with PDCD1 and CD274 Pan-Cancer
To delineate potential molecular mechanisms surrounding the differing clinical rele-
vance of PDCD1/CD274, co-expression analysis was undertaken. Using the same studies
as in the previous section per cancer type, co-expressed genes with a cut-off of ≥0.6 or
≤−0.6 (Spearman’s correlation coefficient) were identified using cBioPortal [19,20]. After
following the filtering process described in the Materials and Methods, the genes shown
below in Table 1 were identified as being significantly co-expressed with CD274 or PDCD1
in multiple cancers:
Table 1. Pan-cancer CD274 and PDCD1 co-expressed genes. In brackets after each gene is the number
of cancers in which the gene was found to be significantly co-expressed with CD274 or PDCD1. For
positive correlations, a gene was taken forward if it appeared in over half (eight of fifteen) of selected
cancers. For negative correlations, due to the far smaller number of identified genes, genes were
taken forward if they appeared co-expressed in more than one cancer. Genes correlated with PDCD1
underwent a further filtering process to remove co-expressed genes that appeared to be specifically T







PDCD1LG2 (12) GATD3A (2) SH2D1A (13)
GBP5 (11) COX19 (2) ACAP1 (12)
CD80 (9) DNASE1 (2) ARHGAP9 (12)
GBP1 (8) DUS1L (2) CXCR6 (12)
JAK2 (8) PTPRCAP (12)
SAMD9L (8) RASAL3 (12)
LCP2 (8) GZMK (11)





























Although positively correlated and negatively correlated genes were identified for
CD274, there were no genes negatively correlated with PDCD1 that remained following
the filtration process described in the Materials and Methods. Therefore, only positively
correlated genes are shown for PDCD1.
2.3. Assessing Clinical Relevance of Co-Expressed Genes
After identifying the co-expressed genes to be taken forward (Table 1), genes under-
went Kaplan–Meier survival analysis using the same studies and approach as described
previously. Table 2 below summarizes the results obtained for the CD274-correlated genes.
Table 2. Statistically significant Kaplan–Meier results for genes correlated with CD274. It should be noted that the






















Cervical N/A N/A N/A N/A
Liver N/A CCR5 DNASE1 N/A
Ovarian N/A CD80 N/A DUS1L
Esophageal N/A N/A N/A N/A
Pancreatic N/A N/A N/A GATD3A
Gastric N/A N/A N/A DUS1L
Head and Neck N/A CCR5 GATD3A N/A
Lymphoma SAMD9L N/A N/A N/A
Breast N/A JAK2, LCP2, SAMD9L N/A DUS1L






Lung N/A N/A N/A N/A
Renal CD80, GBP1, LCP2 JAK2 COX19, DNASE1,DUS1L N/A
Bladder N/A JAK2 N/A DNASE1
Mesothelioma N/A N/A N/A N/A
It should be noted that although CCR5 produced a statistically significant Kaplan–
Meier plot for breast cancer, it has not been included in the table due to its expression
status impacting patient survival differentially across different time points. For the first
120 months, high expression was evidently beneficial, but this effect flipped after this time-
point.
Strikingly, it is immediately apparent that there is a series of cancer-specific gene
associations with survival for both the genes that were found to be positively associated
with CD274 (CCR5, CD80, GBP1, GBP5, JAK2, LCP2, PDCD1LG2, and SAMD9L) and those
showing a negative correlation (COX19, DNASE1, DUS1L, and GATD3A). For example,
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DUS1L, a gene negatively correlated with CD274, was shown in ovarian, gastric, and
breast cancer to be beneficial at high levels of expression. This contrasts with the finding in
melanoma and renal cancer, where low expression was beneficial for patients. Similarly, low
expression of SAMD9L, positively correlated with CD274, was beneficial for lymphoma
patients, whereas high expression of the same gene was beneficial for melanoma and
breast cancer patients. These differences may provide insight into the differing molecular
networks underlying the response to immunotherapy.
The same analysis was performed for PDCD1-correlated genes, though, as stated, there
were no negatively correlated genes taken forward at this stage of the analysis. Table 3
below summarizes the data:
Table 3. Statistically significant Kaplan–Meier results for genes positively correlated with PDCD1. It should be noted that
the mesothelioma study included (Mesothelioma (TCGA, Firehose Legacy)) lacked usable Kaplan–Meier survival data.
Cancer Positively Correlated Genes Where LowExpression Is Beneficial for Patients (p ≤ 0.05)
Positively Correlated Genes Where High
Expression Is Beneficial for Patients (p ≤ 0.05)
Cervical N/A
ACAP1, CST7, CXCR6, GPR171, GZMH, GZMK,
GZMM, JAKMIP1, MAP4K1, P2YR10, PSTPIP1,
RASAL3, SH2D1A, TBC1D10C, ZNF831
Liver N/A
ACAP1, CD96, CST7, CXCR6, GIMAP5, GPR171,
GZMH, GZMK, IKZF1, NKG7, P2RY10, PYHIN1,
SH2D1A, TBC1D10C, TRAF3IP3, ZNF831
Ovarian N/A N/A
Esophageal RASAL3 N/A
Pancreatic N/A SEPTIN1, ZNF831
Gastric N/A IL21R, JAKMIP1
Head and Neck N/A
ACAP1, CD96, CST7, CXCR6, GPR171, GZMK,
GZMM, IKZF1, IL21R, LTA, MAP4K1, NKG7,
P2RY10, PTPRCAP, PYHIN1, RASAL3, SEPTIN1,
SH2D1A, TBC1D10C, TRAF3IP3, ZNF831
Lymphoma ACAP1
Breast N/A
ACAP1, CD96, CST7, CXCR6, GPR171, GZMA,
GZMH, GZMK, GZMM, HCST, IKZF1, MAP4K1,




ACAP1, ARHGAP9, CD96, CST7, CXCR6, GIMAP5,
GPR171, GZMA, GZMH, GZMK, GZMM, HCST,
IKZF1, IL21R, JAKMIP1, LTA, MAP4K1, NKG7,
P2RY10, PSTPIP1, PTPRCAP, PYHIN1, RASAL3,
SEPTIN1, SH2D1A, TBC1D10C, TRAF3IP3, ZNF831
Lung N/A
ARHGAP9, CXCR6, GPR171, IKZF1, LTA, MAP4K1,
PSTPIP1, PTPRCAP, PYHIN1, RASAL3, SEPTIN1,
TBC1D10C, TRAF3IP3
Renal
ACAP1, ARHGAP9, CXCR6, GPR171, GZMH,
GZMM, HCST, IL21R, LTA, MAP4K1, PTPRCAP,
RASAL3, TBC1D10C
GIMAP5
Bladder N/A CD96, CXCR6, GPR171, GZMA, GZMH, MAP4K1,PTPRCAP, PYHIN1, SEPTIN1, SH2D1A
Mesothelioma N/A N/A
Similar to the striking differences observed with the CD274-correlated genes, there are
again some differences with the PDCD1-correlated genes that are immediately apparent
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between cancers. Renal cancer in particular stands out, with the majority of the genes
demonstrating low expression to be beneficial for patients. Comparatively, high expression
of the same genes was shown to be beneficial in the majority of the other cancer types.
Similarly, genes that were significantly associated with survival in the majority of cancers
had no such effect in esophageal cancer. These potential differences could go some way
to explaining the differing role that PDCD1 expression has on patient survival, given
that esophageal cancer was distinct from the other four cancers in that low PDCD1 was
beneficial for esophageal cancer patients (Figure 2C). This again highlights the cancer-
specific networks that may exist and signposts a need for delineation of analysis for
individual types of cancer.
2.4. Identification of microRNAs Targeting CD274, PDCD1, and Their Correlated Genes
To further elucidate potential mechanisms surrounding CD274/PDCD1 and their cor-
related genes, the miRDB microRNA database [22] and the miRabel microRNA database [23]
were used to identify potential microRNAs that target the genes of interest. Using a score
of ≥80 as the threshold for miRDB and a score of ≤0.05 for miRabel, microRNAs were
collated for CD274, PDCD1, and their correlated genes. Following the filtering process
described in the Materials and Methods, a total of 49 unique microRNAs were identified
that appeared in both databases, shown below in Table 4:
Table 4. MicroRNAs identified in both miRDB and miRabel that putatively target CD274, PDCD1,
or their correlated genes. Forty-seven of 49 microRNAs targeted a gene positively correlated with
CD274/PDCD1; 2 of 49, indicated by an asterisk (*), targeted a gene negatively correlated with CD274.
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Table 4. Cont.





















2.5. Assessing Clinical Relevance of the microRNAs Targeting CD274/PDCD1-Related Genes
After identifying the microRNAs described above, they were then screened for their
importance in patient survival using OncomiR [24]. The findings from OncomiR are
summarized in the heatmap (Figure 3) below:
Overall, Figure 3 above summarizes the primary finding of the OncomiR analysis,
which is the identification of 130 significant survival associations for 46 microRNAs across
fourteen groups of cancer. Individual survival results can be seen in File S5. No microRNA
selected was significantly associated with survival in lymphoma, hence its exclusion
from the heatmap. Although the vast majority of microRNAs showed effects which are
evidently clear in Figure 3, hsa-miR-135a-5p and hsa-miR-584-5p showed multiple effects
on colorectal and renal cancer respectively. Low expression of hsa-miR-135a-5p was
significantly beneficial for colon cancer patients, whilst high expression of hsa-miR-135a-
5p was significantly beneficial for rectal cancer patients. Interestingly, hsa-miR-584-5p
demonstrated mixed effects on renal cancers, with high expression being significantly
beneficial for kidney renal clear cell carcinoma patients, whereas low expression was
significantly beneficial for kidney renal papillary cell carcinoma patients.
Another pattern that immediately becomes apparent is the trend for renal cancer
to exhibit opposite survival relationships to other cancer types. Similar to the Kaplan–
Meier survival analysis of CD274/PDCD1-correlated genes (Tables 2 and 3), many of the
microRNAs showed an opposite effect on survival for renal cancer patients compared
to other cancer types, e.g., high expression of hsa-miR-142-5p was beneficial in cervical
cancer, head and neck cancer, melanoma, and lung cancer, but low expression of the same
microRNA was beneficial in renal cancer. Similarly, high expression of hsa-miR-146b-5p,
hsa-miR-15a-5p, hsa-miR-16-5p, and hsa-miR-377-3p was beneficial for pancreatic cancer
patients, whereas low expression of the same microRNAs was beneficial for renal cancer
patients. There are numerous trends and findings to be seen in the OncomiR survival
analysis in Figure 3, but the most striking is again the opposing impact the microRNAs
have on survival for renal cancer patients.




Figure 3. Heatmap of the clinical relevance of the microRNAs from Table 4. MicroRNAs are shown on the y-axis whilst
cancer types are shown on the x-axis. A green color indicates that high expression of the microRNA is significantly beneficial
for that cancer type (p ≤ 0.05), whilst red indicates that low expression of the microRNA is significantly beneficial for
survival (p ≤ 0.05). Orange indicates mixed effects, whilst black indicates no significant relationship (p > 0.05) or, in the case
of hsa-miR-568, no output data from OncomiR [24].
2.6. Identification of Putative Repurposed Drugs Targeting PDCD1/CD274
Co-Expressed Genes/Proteins
Due to the potential clinical relevance of the shortlisted genes and microRNAs de-
scribed previously, the DRUGSURV database [25,26] was used to explore if any of the pro-
teins generated from the genes of interest identified above were the target of an approved
drug. Five proteins (tyrosine-protein kinase JAK2, CCR5, CXCR6, lymphotoxin-alpha
(LTA) and mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1)) were found
to be modulated by at least one drug (Table 5). The largest number of drugs was identified
for the kinases, with 14 drugs targeting JAK2 and four targeting MAP4K1, followed by the
chemokine receptors with four for CXCR6 and three for CCR5, with a single drug known
to target the TNF-family cytokine LTA. There was some overlap in the drug targets, with
one drug (disulfiram) targeting both CCR5 and CXCR6, and both sunitinib and dasatinib
known to have affinity for both JAK2 and MAP4K1.
The indicated use includes a range of cancers for the drugs targeting the kinases,
including cancer types used in this study. Although the drugs targeting the other proteins
have not been approved for use in cancer, drugs targeting CXCR6 and/or CCR5 have been
taken forward into clinical trials in the cancer setting.
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Table 5. Approved drugs.
Indication
Drug Target Cancer Other Cancer Trial
Cytarabine JAK2 Leukemia Yes













Azathioprine JAK2 No Rheumatoid arthritis,transplant rejection Yes
Floxuridine JAK2 Liver cancerand metastases Yes






Albendazole JAK2 No Anthelmintic
Triamterene JAK2 No Edema











keratitis due to herpes
simplex virus
Yes





Maraviroc CCR5 No HIV-1 Yes
Clioquinol CXCR6 No Antifungal Terminated (Phase 1)









Nilotinib MAP4K1 Leukemia Yes
Sorafenib MAP4K1 Liver, renal Yes
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3. Discussion
This study utilized a bioinformatic approach to explore potential factors contributing
to the PDCD1/CD274 network on a pan-cancer basis. Through this approach, several genes
commonly co-expressed with PDCD1/CD274 were identified and their clinical importance
ascertained through Kaplan–Meier plots. Further molecular insights were generated by
assessing potential links to microRNAs, which were in turn assessed for clinical relevance.
Finally, potential repurposed drugs were identified which target the genes that commonly
co-express with PDCD1/CD274.
It is interesting to note that for breast cancer, renal cancer, and melanoma, high CD274
expression was statistically significantly beneficial for patients. Whilst this was initially
surprising, as it is logical that CD274 expression would result in immune evasion and
thereby cancer survival, a recent pooled analysis from 1062 melanoma patients showed
that CD274 expression had no significant relationship with overall survival but that high
CD274 expression was significantly associated with lymph node metastases [27]. As such,
it is highly probable that indications of survival will be cohort specific. A similar pattern
was seen for PDCD1 expression, with four of five cancers demonstrating that high PDCD1
expression was statistically significantly beneficial. Comparatively, esophageal cancer
showed the opposite, with low expression being beneficial for patients (Figure 2C).
This difference could explain the starkly different Kaplan–Meier plots that were
identified for the PDCD1/CD274-correlated genes, with the majority of cancers showing
the same pattern for the co-expressed genes whilst esophageal and renal were notably
different. Importantly, these differences could provide insight into the different underlying
networks supporting the immunotherapy response and provide an opportunity for the
identification of cancer type-specific adjuvants to immunotherapeutic agents.
Subsequent to the gene-level analysis was the microRNA analysis. Although 49
microRNAs were identified as linked to the CD274/PDCD1 network and many showed
survival relationships (with 130 significant survival relationships being identified across
fourteen cancer types), it is beyond the scope of this article to validate each of them.
However, literature validation of a subset shows good consistency with previous research.
For instance, a 2017 article demonstrated that hsa-miR-142-5p promotes cell growth and
migration in renal cell carcinoma; therefore, low hsa-miR-142-5p expression would be
beneficial for patients [28]. This is consistent with the data shown in Figure 3, where low
expression of hsa-miR-142-5p was significantly beneficial for patients.
A similar outcome was that hsa-miR-337-3p was identified as potentially capable
of targeting JAK2 and Table 2 demonstrates that high expression of the JAK2 gene was
beneficial in several cancers, including renal and bladder cancer. In concordance with this,
high expression of hsa-miR-337-3p was associated with poor outcomes in these cancer types
(Figure 3). There is also experimental evidence to support the ability of this microRNA to
suppress expression of JAK2 [29,30] via decreased luciferase activity upon co-transfection of
the JAK2 3′UTR luciferase reporter and hsa-miR-337-3p, and decreased JAK2 protein levels
upon overexpression of the microRNA in liver cancer cell lines. It should be noted, however,
that the study by Zuo and colleagues [29] was conducted in hepatocellular carcinoma cells
and hsa-miR-337-3p acted as a tumor suppressor and suppressed proliferation and invasion.
Although Figure 3 does not demonstrate a significant survival effect for hsa-miR-337-3p
in liver cancer, this points to patient cohort-specific differences and the possibility of
differential survival relevance between different cancer types.
Figure 3 also shows high expression of hsa-miR-146a-5p to be beneficial in several
cancers (cervical, ovarian, breast, head and neck, and gastric). The tumor-suppressive role
of this microRNA is well established [31], but in other cancer types, this microRNA can
act to promote cancer, working as an oncomiR [31]. Within ovarian cancer, the protective
role of hsa-miR-146a-5p may be explained in part by its effect on superoxide dismutase
2 (SOD2), which leads to increased levels of reactive oxygen species (ROS), decreased
proliferation, increased apoptosis, and enhanced sensitivity to chemotherapy [32].
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From the panel of identified microRNAs, the one showing a significant survival
association with the greatest number of cancers was hsa-miR-125-5p. The pattern was
primarily for high expression of hsa-miR-125-5p to be good for patient outcomes (in
pancreatic cancer, lung cancer, renal cancer, bladder cancer, and mesothelioma) which is in
agreement with a recent metanalysis of patient data [33]. The mechanistic understanding
of this effect is supported by a body of evidence that shows that hsa-miR-125-5p acts
as a tumor suppressor in a variety of cancers. In non-small cell lung cancer [34,35] and
lung adenocarcinoma [36], expression of hsa-miR-125-5p was associated with reduced
cell growth, increased apoptosis, and increased differentiation. In vitro models have also
identified a role for this microRNA in inhibiting invasion and migration of lung cancer
cells [37]. Identified in this study as a potential modulator of DUS1L, this gene has not been
experimentally verified to be the target of hsa-miR-125-5p. However, a range of identified
targets are involved in the KRAS and NF-kappaB pathways, for example, SOS1, GRB2,
IQGAP1, RALA, RAF-1, IKKβ, AKT2, ERK2 and KRAS [38], STAT3 [39], and antiapoptotic
proteins such as BCL2, BCL2L12, MCL1 [40], BAP1 [41], and TMPRSS4 [36]. Contrary to
the general trend, however, our data showed that high expression of hsa-miR-125-5p was
detrimental in both gastric cancer and melanoma (Figure 3). Despite this, there is evidence
in the literature that tumor expression of hsa-miR-125-5p can suppress proliferation in
gastric cancer [42] and melanoma [43], together with increased senescence in melanoma [44].
This discrepancy may be explained at least in part by effects of microRNA on the tumor
microenvironment. In melanoma, exosomal hsa-miR-125-5p was found to influence tumor-
associated macrophages [45] and, potentially via targeting of lysosomal acid lipase A
(LIPA), helps in macrophage polarization to a tumor-promoting phenotype.
A 2016 study compared microRNA expression in short-surviving and long-surviving
mesothelioma patients [46] and identified that hsa-miR-17-5p, hsa-miR-22-3p, hsa-miR-
27b-3p, and hsa-miR-93-5p were all expressed at a higher level in short-surviving patients
versus long-surviving patients. This is partially consistent with the data presented in
Figure 3, where low expression of hsa-miR-17-5p and hsa-miR-93-5p was significantly
beneficial for patient survival. However, Figure 3 also shows that high expression of
hsa-miR-22-3p and hsa-miR-27b-3p was beneficial for patients. Notably, the 2016 study [46]
did not identify hsa-miR-1323, hsa-miR-216a-5p, hsa-miR-380-3p, hsa-miR-497-5p, hsa-
miR-580-3p, hsa-miR-125b-5p, and hsa-miR-125a-5p to be important for patient survival.
Differences could arise due to patient cohort-specific differences and analytical methods,
as well as the number of patients included (n = 16 for the 2016 study [46] and n = 86 for the
mesothelioma study from OncomiR [24]).
This study has ultimately identified a significant number of microRNAs which have
prognostic importance and may be related to the molecular network of immune checkpoint
blockade. Similarly, the cancer-specific differences of the co-expressed genes highlighted in
Tables 2 and 3 also warrant further investigation, particularly in the case of renal cancer
which was surprisingly oppositional to the other cancer types included.
The purpose of the DRUGSURV analysis was to identify repositionable drugs that
could be used to target the proteins that correlated with PDCD1/CD274. In total, 23 drugs
were identified targeting various members of the network. In theory, as the genes correlate
with PDCD1/CD274, targeting them in conjunction with immunotherapy could boost
the response and improve outcomes, or perhaps allow for lower dosages to be used
whilst maintaining therapeutic effects. Although in vitro or in vivo validation has not
been performed in this study, there is literature supporting this. For example, disulfiram,
targeting CCR5 and CXCR6 (Table 5), has been shown recently to have a synergistic effect
with an anti-PD-1 antibody (clone J43, BioXcell ) [47]. Disulfiram, clinically approved for
alcoholism, increased the numbers of cytotoxic CD8+ T cells in the tumor when combined
with the anti-PD-1 antibody and ultimately inhibited tumor growth and metastasis [47].
The fact that disulfiram has been identified herein (Table 5) again provides validation
to the approach utilized, and indicates that the thirteen other drugs that currently do
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not have a cancer indication (Table 5) could be of potential clinical utility, possibly as
immunotherapeutic adjuvants.
A limitation of the present study is that only mRNA expression has been examined,
and hence it is largely single-omics analyses other than the use of microRNA data in
concurrence with mRNA expression. Recent reports highlight the importance of multi-
omics investigation, as it allows for the flow of information at multiple biological levels to
be analyzed and the data to be examined holistically [48–50]. That said, several promising
avenues have been identified in the current study that warrant further investigation at
the in vitro or in vivo level. Immunotherapy in general holds significant promise, but
any clinical trial pertaining to it should interpret findings with caution, as research has
shown that surrogate clinical trial endpoints such as progression-free survival are not fully
reflective of overall survival and therefore caution should be used when interpreting data
that do not include overall survival [51]. Ultimately, this research has identified multiple
candidate genes, microRNAs, and drugs to be further investigated at the in vitro or in vivo
level that could have impact in the immune checkpoint arena.
4. Materials and Methods
4.1. Study Selection
In order to interrogate the role of CD274 and PDCD1 on a pan-cancer basis, the
cBioPortal database (https://www.cbioportal.org/, accessed on 29 March 2021) was ac-
cessed [19,20]. This database contains a range of patient-level multi-omics data that are
easily accessible and contains data from over 300 individual studies/analyses.
To begin, to ensure consistency across the individual studies, only studies including
RNA-seq data were included at the initial CD274/PDCD1 screen. Studies containing
“mRNA expression z-scores relative to diploid samples (RNA Seq V2 RSEM)” for Kaplan-
Meier analysis as well as “mRNA expression (RNA Seq V2 RSEM)” for co-expression were
included and mapped to fifteen cancer types for which CD274/PDCD1 inhibition was an
approved therapeutic strategy. This led to the studies included below in Table 6.
Table 6. Studies included from cBioPortal at the initial screening stage. N.B. Uveal melanoma was excluded from all
melanoma analyses due to this cancer’s known poor response to immune checkpoint blockade compared to cutaneous
melanoma [52].



























Int. J. Mol. Sci. 2021, 22, 5478 15 of 20
Table 6. Cont.


























































































4.2. Assessing the Impact of Pan-Cancer PDCD1 and CD274 Expression
After selecting the datasets described above in Table 6, for each cancer type in turn, all
relevant studies were selected on cBioPortal and “Explore Selected Studies” was selected.
Expression of CD274 and PDCD1 in turn was determined for all patients selected from
each cancer type and patients were split into low and high expression based on the median
value. “mRNA expression z-scores relative to diploid samples (RNA Seq V2 RSEM)” was
used as the “type” of mRNA expression analysis. A Kaplan–Meier plot was then computed
based on the two groups (low and high expression of CD274/PDCD1) to determine the
putative role of each gene in patient survival. Raw p ≤ 0.05 was considered statistically
significant and the determination of low or high expression being beneficial for the patient
was determined by examination of the overall pattern of the curve.
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4.3. Identifying Co-Expressed Genes/Proteins Per Cancer Type
After selecting the same studies per cancer type described in the previous section and
shown in Table 6, the “Query by Gene” function on cBioPortal was utilized with CD274
or PDCD1 as an input to identify genes that co-expressed with them. “mRNA expression
z-scores relative to diploid samples (RNA Seq V2 RSEM)” was again selected as the “type”
of mRNA expression analysis. The default “Patient/Case Set” was used for each cancer
type (though it should be noted that this defaults to “Complete samples”, meaning some
patients with expression data could have been excluded). The raw co-expression outputs
were downloaded and processed to filter and include correlations (Spearman’s correlation
coefficient) that were ≤−0.6 or ≥0.6 (“moderately strong” [61]) per individual study with
a maximum of 100 positively correlated and 100 negatively correlated per individual study.
Gene lists were then collated per study for each individual cancer type.
4.4. Identifying Common Pan-Cancer Co-Expressed Genes
After identifying the co-expressed genes for individual cancer studies, summary tables
were created which collated the information on a pan-cancer level. Four tables in total were
created: genes positively correlated with CD274; genes negatively correlated with CD274;
genes positively correlated with PDCD1; and genes negatively correlated with PDCD1.
After collating the information for the summary tables, final gene lists of interest that
were positively correlated with CD274 or PDCD1 were selected by filtering to include only
genes that appeared in at least eight (more than half) out of fifteen cancers. For negatively
correlated genes, due to the significantly fewer negative correlations identified, genes were
taken forward for further analysis if they appeared in at least two different cancers. Files S1
and S2 contain the co-expression data analysis for CD274 and PDCD1, respectively. In the
case of PDCD1 co-expressed genes, the list underwent a further filtering process due to
the possibility of T cell-related genes appearing in the co-expression (from TILs, see File
S3). This process entailed screening the function of the co-expressed genes and excluding
those that appeared to be specifically T cell-related rather than tumor cell-related. The final
gene lists shown in Table 1 were used to create Kaplan–Meier plots using the same criteria
described previously.
4.5. Identifying Putative microRNAs Targeting Genes of Interest
To gain potential mechanistic insight into the CD274/PDCD1-associated genes, the
miRDB database (http://mirdb.org/, accessed on 28 April 2021) was employed [22]. Genes
identified from the previous section (Table 1) were entered in turn into the database to
identify putative microRNAs that regulate the gene lists of interest. The miRDB site states
that a prediction score > 80 is most likely to be real; therefore, 80 was used as the minimum
score for the microRNA for it to be included.
Next, due to the known issue of false positives present within microRNA target pre-
diction programs [62], a second database, miRabel (http://bioinfo.univ-rouen.fr/mirabel/,
accessed 10 May 2021), was also accessed [23]. This database integrates information from
miRanda [63], PITA [64], SVmicrO [65], and TargetScan [66] to provide an aggregate score
with a recommended threshold of 0.05 (the lower the score the better) [23]. Genes were
entered in turn into the miRabel database and microRNAs putatively targeting the genes
of interest with a miRabel score ≤ 0.05 were extracted. Finally, the microRNA lists from
miRDB and miRabel were cross-referenced to further reduce the likelihood of false posi-
tives, ultimately leading to the final list of microRNAs shown in Table 4. The output from
each database and the cross-referencing analysis can be seen in File S4.
4.6. Screening the Clinical Relevance of Putative microRNAs Using OncomiR
In order to validate the clinical relevance of the identified microRNAs in Table 4, On-
comiR (http://oncomir.org/, accessed on 12 May 2021) [24] was accessed. Each microRNA
in turn was entered into the “Survival Outcome” section of OncomiR with p ≤ 0.05 used
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as the significance criteria. Only cancers relevant to this study were included within the
results. Full OncomiR results can be seen in File S5.
4.7. Identification of Putative Repurposed Drugs through DRUGSURV
Following the identification of genes of interest (Table 1), each gene in turn was
queried through the DRUGSURV (http://www.bioprofiling.de/GEO/DRUGSURV/index.
html, accessed on 25 April 2021) database [25,26] to identify potential approved drugs
that directly targeted each gene product. Links to whether the drug was indicated for a
particular cancer type, or was in clinical trials, or had experimental data supporting its use,
were verified using the DrugCentral (https://drugcentral.org/, accessed on 13 May 2021)
database [67] and by literature searches.
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